Senti Biosciences (SNTI) Equity Average (2021 - 2025)

Senti Biosciences has reported Equity Average for 5 years, with the latest figure at $6.9 million in Q4 2025.

• For the quarter ending Q4 2025, Equity Average fell 67.08% year-over-year to $6.9 million; the trailing twelve-month figure through Dec 2025 stood at $6.9 million (down 67.08% YoY), and the FY2025 full-year result was $15.6 million, down 66.25% from the prior year.
• Equity Average for Q4 2025 stood at $6.9 million, down from $16.4 million in the prior quarter.
• The five-year high for Equity Average was $147.3 million in Q3 2022, with the low at -$116.6 million in Q1 2022.
• Average Equity Average over 5 years is $28.0 million, with a median of $31.3 million recorded in 2025.
• Year-over-year, Equity Average soared 546.22% in 2023 and plunged 72.21% in 2024.
• Tracing SNTI's Equity Average over 5 years: stood at -$106.4 million in 2021, then surged by 225.74% to $133.8 million in 2022, then slumped by 44.0% to $74.9 million in 2023, then sank by 72.21% to $20.8 million in 2024, then sank by 67.08% to $6.9 million in 2025.
• The last three Equity Average figures came in at $6.9 million (Q4 2025), $16.4 million (Q3 2025), and $31.3 million (Q2 2025), per Business Quant data.

Peer Comparison